Expansion of CD16-Negative Natural Killer Cells in Melanoma Patients
Author Information
Author(s): Shernan G. Holtan, Douglas J. Creedon, Michael A. Thompson, Wendy K. Nevala, Svetomir N. Markovic
Primary Institution: Mayo Clinic Graduate School of Medicine
Hypothesis
CD16− NK cells are expanded in the peripheral blood of melanoma patients as previously described in normal pregnancy.
Conclusion
The study found that patients with metastatic melanoma have a significant expansion of CD16− NK cells in their peripheral blood compared to healthy controls.
Supporting Evidence
- Patients with melanoma had a median of 7.4% CD16− NK cells compared to 3.0% in controls.
- Expansion of CD16− NK cells was associated with elevated plasma TGF-β levels.
- The study suggests exploring anti-TGF-β therapy to restore NK function in melanoma.
Takeaway
This study shows that people with melanoma have more of a certain type of immune cell called CD16− NK cells in their blood, which might help us understand how to treat the disease better.
Methodology
NK subset analysis was performed on the peripheral blood of 41 patients with untreated metastatic melanoma and 29 healthy controls using flow cytometry.
Participant Demographics
41 patients with untreated metastatic melanoma and 29 healthy controls.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website